P01.029  Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)

A. R. Korshoej; S. Lukacova; J. H. Sørensen; F. L. Hansen; N. Mikic; A. Thielscher; S. O. S. Cortnum; T. L. Guldberg; Y. Lassen-Ramshad; C. Rahbek; K. E. Severinsen; G. B. von Oettingen

doi:10.1093/neuonc/noy139.071

P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)

A. R. Korshoej, S. Lukacova, J. H. Sørensen, F. L. Hansen, N. Mikic, A. Thielscher, S. O. S. Cortnum, T. L. Guldberg, Y. Lassen-Ramshad, C. Rahbek, K. E. Severinsen, G. B. von Oettingen

Aarhus University Hospital

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Neuro-Oncology
Volume	20
Issue number	suppl_3
Pages (from-to)	iii234-iii235
Number of pages	2
ISSN	1522-8517
DOIs	https://doi.org/10.1093/neuonc/noy139.071
Publication status	Published - 2018
Event	13th Meeting of the European Association of Neurooncology - Stockholm, Sweden Duration: 10 Oct 2018 → 14 Oct 2018 Conference number: 13

Conference

Conference	13th Meeting of the European Association of Neurooncology
Number	13
Country/Territory	Sweden
City	Stockholm
Period	10/10/2018 → 14/10/2018

Access to Document

10.1093/neuonc/noy139.071

OpenUrl availability

Full text

Cite this

Korshoej, A. R., Lukacova, S., Sørensen, J. H., Hansen, F. L., Mikic, N., Thielscher, A., Cortnum, S. O. S., Guldberg, T. L., Lassen-Ramshad, Y., Rahbek, C., Severinsen, K. E., & von Oettingen, G. B. (2018). P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1). Neuro-Oncology, 20(suppl_3), iii234-iii235. https://doi.org/10.1093/neuonc/noy139.071

@article{fa02500db81e4c12a9b8de97935a22f8,

title = "P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)",

author = "Korshoej, {A. R.} and S. Lukacova and S{\o}rensen, {J. H.} and Hansen, {F. L.} and N. Mikic and A. Thielscher and Cortnum, {S. O. S.} and Guldberg, {T. L.} and Y. Lassen-Ramshad and C. Rahbek and Severinsen, {K. E.} and {von Oettingen}, {G. B.}",

year = "2018",

doi = "10.1093/neuonc/noy139.071",

language = "English",

volume = "20",

pages = "iii234--iii235",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "suppl_3",

note = "13th Meeting of the European Association of Neurooncology ; Conference date: 10-10-2018 Through 14-10-2018",

}

Korshoej, AR, Lukacova, S, Sørensen, JH, Hansen, FL, Mikic, N, Thielscher, A, Cortnum, SOS, Guldberg, TL, Lassen-Ramshad, Y, Rahbek, C, Severinsen, KE & von Oettingen, GB 2018, 'P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)', Neuro-Oncology, vol. 20, no. suppl_3, pp. iii234-iii235. https://doi.org/10.1093/neuonc/noy139.071

P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1). / Korshoej, A. R.; Lukacova, S.; Sørensen, J. H. et al.
In: Neuro-Oncology, Vol. 20, No. suppl_3, 2018, p. iii234-iii235.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)

AU - Korshoej, A. R.

AU - Lukacova, S.

AU - Sørensen, J. H.

AU - Hansen, F. L.

AU - Mikic, N.

AU - Thielscher, A.

AU - Cortnum, S. O. S.

AU - Guldberg, T. L.

AU - Lassen-Ramshad, Y.

AU - Rahbek, C.

AU - Severinsen, K. E.

AU - von Oettingen, G. B.

N1 - Conference code: 13

PY - 2018

Y1 - 2018

U2 - 10.1093/neuonc/noy139.071

DO - 10.1093/neuonc/noy139.071

M3 - Conference abstract in journal

SN - 1522-8517

VL - 20

SP - iii234-iii235

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - suppl_3

T2 - 13th Meeting of the European Association of Neurooncology

Y2 - 10 October 2018 through 14 October 2018

ER -

Korshoej AR, Lukacova S, Sørensen JH, Hansen FL, Mikic N, Thielscher A et al. P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1). Neuro-Oncology. 2018;20(suppl_3):iii234-iii235. doi: 10.1093/neuonc/noy139.071